Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 5/20 | 0.35 |
| ▸ | EDNRA | P25101 | 3/20 | 0.35 |
| ▸ | CASP7 | P55210 | 4/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613110 | 0.80 | JAK2 (0.38) | ALOX5APCASP3EDNRACASP7CNR2 | |
| SCHEMBL25627065 | 0.75 | CNR2 (0.31) | CNR2 | |
| SCHEMBL25613101 | 0.74 | JAK2 (0.34) | CASP3CASP7JAK2JAK3 | |
| SCHEMBL25627063 | 0.70 | — | — | |
| SCHEMBL25627396 | 0.67 | KDM4E (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL25613114 | 0.66 | CHRNB4 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNB1 | |
| SCHEMBL25613112 | 0.63 | TDP1 (0.35) | — | |
| SCHEMBL8541198 | 0.62 | CASP3 (0.38) | CASP3CASP7 | |
| SCHEMBL13726972 | 0.62 | PER2 (0.33) | CNR2 | |
| SCHEMBL13269872 | 0.62 | CASP3 (0.46) | CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | ALOX5AP 3258/4885CASP3 26/4885EDNRA 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.